Читать книгу Interventional Cardiology - Группа авторов - Страница 161

1 1 Urban P, Meredith IT, Abizaid A, et al. Polymer‐free Drug‐Coated Coronary Stents in Patients at High Bleeding Risk. N. Engl. J. Med. 2015, 373 (21), 2038–47.

2 2 Le May M, Wells G, So D, et al. Safety and Efficacy of Femoral Access vs Radial Access in ST‐Segment Elevation Myocardial Infarction: The SAFARI‐STEMI Randomized Clinical Trial. JAMA Cardiol.2019, 5 (2), 126–134.

3 3 Stone GW, Sabik JF, Serruys PW, et al. Everolimus‐Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N. Engl. J. Med. 2016, 375 (23), 2223–2235.

4 4 Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter‐based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN‐OFF MED): a randomised, sham‐controlled, proof‐of‐concept trial. The Lancet, 2017, 390 (10108), 2160–2170.

5 5 Kamalesh M, Sharp TG, Tang XC, et al. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J. Am. Coll. Cardiol. 2013, 61 (8), 808–816.

6 6 De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve‐guided PCI versus medical therapy in stable coronary disease. N. Engl. J. Med. 2012, 367 (11), 991–1001.

7 7 Price MJ, Berger PB, Teirstein PS, et al. Standard‐ vs high‐dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA ‐ J. Am. Med. Assoc. 2011, 305 (11), 1097–1105.

8 8 Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N. Engl. J. Med. 2011, 365 (10), 883–891.

9 9 Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2011, 365 (11), 981–992.

10 10 Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2013, 369 (22), 2093–2104.

11 11 Kandzari DE, Mauri L, Koolen JJ, et al. Ultrathin, bioresorbable polymer sirolimus‐eluting stents versus thin, durable polymer everolimus‐eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. The Lancet 2017, 390 (10105), 1843–1852.

12 12 Windecker S, Haude M, Neumann FJ, et al. Comparison of a novel biodegradable polymer sirolimus‐eluting stent with a durable polymer everolimus‐eluting stent: Results of the randomized BIOFLOW‐II trial. Circ. Cardiovasc. Interv. 2015, 8 (2).

13 13 Saito S, Tölg R, Witzenbichler B, et al. BIOFLOW‐IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus‐eluting stent in the treatment of subjects with de novo coronary artery lesions: Primary outcome target vessel failure at 12 months. EuroIntervention 2019, 15 (11), E1006–E1013.

14 14 Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic‐Valve Replacement in Intermediate‐Risk Patients. N. Engl. J. Med. 2017, 376 (14), 1321–1331.

15 15 Van Mieghem NM, Popma JJ, Deeb GM, et al. Complete 2‐Year Results Confirm Bayesian Analysis of the SURTAVI Trial. JACC Cardiovasc. Interv.2020, 13 (3), 323–331.